



For immediate release 4.00pm: 21 May 2014

RETROSCREEN VIROLOGY GROUP PLC
("Retroscreen" or the "Company")
RESULT OF ANNUAL GENERAL MEETING

Retroscreen Virology Group plc (AIM: RVG), the pioneer of *hVIVO* human challenge models of disease, is pleased to announce that all resolutions proposed at its Annual General Meeting, held at 10am on 21 May 2014, were duly passed.

For further information please contact:

Retroscreen Virology Group plc +44 207 756 1300

Kym Denny (CEO)
Graham Yeatman (FD)

Numis Securities Limited +44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)

Notes to Editors:

Retroscreen Virology Group plc ("Retroscreen") is a rapidly growing UK life sciences company pioneering a technology platform called *hVIVO* which uses human models of disease involving healthy volunteers to study new drugs and investigate disease in a safe, controlled environment.

Retroscreen has established itself as the world leader in this field through the provision of clinical services to third party study sponsors. To date, the Company has conducted over 35 clinical studies, involving more than 1600 volunteers for a range of leading industry, governmental and academic clients.

However, Retroscreen's *hVIVO* platform has a much wider application in helping to understand illness because the Company believes that the best way to understand human disease is by studying it in humans, not laboratory models.